ELTX Stock Forecast 2025-2026
Distance to ELTX Price Targets
ELTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Elicio Therapeutics (ELTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ELTX and similar high-potential opportunities.
Latest ELTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ELTX has a neutral consensus with a median price target of $12.00 (ranging from $12.00 to $12.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $8.00, the median forecast implies a 50.0% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Burns at HC Wainwright & Co., projecting a 50.0% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 50.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELTX Analyst Ratings
ELTX Price Target Range
Latest ELTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2024 | Jones Trading | Soumit Roy | Buy | Initiates | $9.00 |
| Aug 23, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Jun 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| May 22, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| May 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $10.00 |
| Apr 1, 2024 | Oppenheimer | Matthew Biegler | Perform | Reiterates | $0.00 |
| Jan 17, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $11.00 |
| Oct 26, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Assumes | $12.00 |
Elicio Therapeutics Inc. (ELTX) Competitors
The following stocks are similar to Elicio Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elicio Therapeutics Inc. (ELTX) Financial Data
Elicio Therapeutics Inc. has a market capitalization of $131.81M with a P/E ratio of 5.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -309.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Elicio Therapeutics Inc. (ELTX) Business Model
About Elicio Therapeutics Inc.
Develops novel cancer therapies using proprietary technology.
Elicio Therapeutics Inc. generates revenue through the development and commercialization of innovative cancer treatments, leveraging its proprietary Amphiphile Platform to enhance immune responses against cancer. The company focuses on creating therapies for a range of tumors, aiming to improve treatment efficacy and reduce cancer recurrence.
As a key player in the biotechnology sector, Elicio Therapeutics is positioned at the forefront of cancer treatment research, highlighting its commitment to advancing patient-centric healthcare solutions. The company's work in immunotherapy represents a significant opportunity for breakthroughs in the treatment of various cancers.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
32
CEO
Mr. Robert T. Connelly
Country
United States
IPO Year
2021
Website
elicio.comElicio Therapeutics Inc. (ELTX) Latest News & Analysis
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
3 days agoElicio Therapeutics appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective March 24, 2025. The company focuses on developing immunotherapies for cancer.
Elicio Therapeutics' appointment of a new Chief Strategy and Financial Officer signals potential strategic shifts and financial management improvements, impacting investor confidence and stock performance.
Interim results from the AMPLIFY-7P study on ELI-002 for KRAS mutant pancreatic cancer are expected in H1 2025. The global pancreatic cancer market could reach $7.4 billion by 2032.
The upcoming interim analysis of ELI-002 for KRAS mutant pancreatic cancer could signal significant market potential, given the $7.4 billion forecast and high mutation prevalence, influencing investor sentiment.
FDA provided positive feedback on the ELI-002 Phase 3 study design regarding dose, schedule, patient population, and primary endpoint analysis, indicating progress in the development process.
Supportive FDA feedback enhances the credibility and potential success of ELI-002's Phase 3 study, increasing investor confidence in future market approval and revenue potential.
Updated Phase 1 data shows a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for the full study population.
The updated Phase 1 data showing improved median recurrence-free and overall survival rates indicates potential efficacy of the treatment, influencing investor confidence and stock valuation.
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
4 months agoElicio's AMPLIFY-7P Phase 2 study enrollment will finish in Q4 2024, with interim DFS results due in H1 2025. They will also present updated RFS and OS data at the ESMO Congress. The company has a strong cash position.
The progress of AMPLIFY-7P and upcoming data presentations signal potential advancements in cancer treatment, which can influence stock performance and investor sentiment in the biotech sector.
Preliminary data show strong and dose-dependent T cell responses against KRAS mutations and patient-specific neoantigens, indicating potential for targeted therapies.
Durable T cell responses to KRAS mutations and patient-specific neoantigens signal potential advancements in cancer immunotherapy, likely impacting the stock performance of biotech companies involved.
Frequently Asked Questions About ELTX Stock
What is Elicio Therapeutics Inc.'s (ELTX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Elicio Therapeutics Inc. (ELTX) has a median price target of $12.00. The highest price target is $12.00 and the lowest is $12.00.
Is ELTX stock a good investment in 2025?
According to current analyst ratings, ELTX has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELTX stock?
Wall Street analysts predict ELTX stock could reach $12.00 in the next 12 months. This represents a 50.0% increase from the current price of $8.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elicio Therapeutics Inc.'s business model?
Elicio Therapeutics Inc. generates revenue through the development and commercialization of innovative cancer treatments, leveraging its proprietary Amphiphile Platform to enhance immune responses against cancer. The company focuses on creating therapies for a range of tumors, aiming to improve treatment efficacy and reduce cancer recurrence.
What is the highest forecasted price for ELTX Elicio Therapeutics Inc.?
The highest price target for ELTX is $12.00 from Robert Burns at HC Wainwright & Co., which represents a 50.0% increase from the current price of $8.00.
What is the lowest forecasted price for ELTX Elicio Therapeutics Inc.?
The lowest price target for ELTX is $12.00 from Robert Burns at HC Wainwright & Co., which represents a 50.0% increase from the current price of $8.00.
What is the overall ELTX consensus from analysts for Elicio Therapeutics Inc.?
The overall analyst consensus for ELTX is neutral. Out of 3 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are ELTX stock price projections?
Stock price projections, including those for Elicio Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
